STAT

APRIL 4, 2024

… The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective for diabetes and obesity, but is also showing early potential to help with conditions involving the brain, such as mental health disorders, Alzheimer’s, and even, as new study results suggest — Parkinson’s disease , STAT writes.  In

Diabetes 268

Diabetes Biosimilars 268

Express Pharma

AUGUST 8, 2024

Benemae Pharmaceutical’s benaglutide injection (Feisumei) was the first innovator approved for obesity in July 2023 in China followed by Novo Nordisk’s diabetes therapy semaglutide (Wegovy) in June 2024. The global obesity market faces supply issues, prompting Chinese pharma companies to leverage the situation to develop GLP-1 biosimilars.

Biosimilars 102

Biosimilars Diabetes 102

Putting Patients First Blog

JANUARY 27, 2025

The NHC recognizes that Medicare already covers AOMs for patients who are overweight and have comorbid conditions such as diabetes or cardiovascular disease. To further strengthen these efforts, the NHC recommends that CMS adopt additional measures to ensure broad access to generics, biosimilars, and other cost-effective treatments.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Biosimilars Communication Department of Veterans Affairs 40

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

Safe Biologics

APRIL 10, 2023

This will help speed approval, increasing access to biosimilars while promoting safety and building confidence through strong post-market monitoring. The webinars will focus on unintended consequences that may result from the implementation of IRA provisions regarding biologic and biosimilar medicines. Read about the approval here.

Biosimilars 130

Biosimilars Drug Pricing Diabetes Labelling 130

Express Pharma

JANUARY 3, 2025

While India was able to leverage the 2008 patent cliff of small molecules, the same playbook will not work for biologics and biosimilars. Many biopharma companies in India have already leveraged the biosimilar patent cliff. Biocon became the first company from India to launch its biosimilar Hulio in the US in July 2023.

Biosimilars 105

Biosimilars Vaccines Diabetes 105

Big Molecule Watch

FEBRUARY 19, 2025

LLCs (Sanofi) MERILOG (insulin-aspart-szjj), a biosimilar to Novo Nordisk A/Ss (Novo Nordisk) NOVOLOG (insulin aspart), for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Stay tuned to Big Molecule Watch for further developments in the biosimilars market.

Biosimilars 45

Biosimilars Diabetes 45